Impact of postoperative integrated genomic and epigenomic signatures of circulating tumor DNA (ctDNA) on recurrence in resected colorectal cancer: Initial report of a prospective ctDNA monitoring study COSMOS-CRC-01.

作者
Yuichiro Tsukada,Nobuhisa Matsuhashi,Tatsuro Murano,Manabu Shiozawa,Takeshi Kato,Eiji Oki,Masahiro Goto,Yoshinori Kagawa,Akiyoshi Kanazawa,Takashi Ohta,Akira Ouchi,Hideaki Bando,Xiaotong Zuo,Princy Parsana,Kristin Sedgwick Price,Hiroaki Ikematsu,Takayuki Yoshino,Yoshiaki Nakamura
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:40 (4_suppl): 168-168 被引量:8
标识
DOI:10.1200/jco.2022.40.4_suppl.168
摘要

168 Background: Identifying molecular residual disease (MRD) using circulating tumor DNA (ctDNA) analysis after curative surgery can potentially stratify the recurrence risk and facilitate personalization of adjuvant treatment in patients with colorectal cancer (CRC). We conducted a prospective study “COSMOS-CRC-01” to evaluate the utility of a plasma-only ctDNA assay integrating genomic and epigenomic signatures. Methods: Patients with resectable clinical stage 0–III colorectal cancer were eligible. Plasma samples were collected at structured pre- and post-surgical timepoints and analyzed using Guardant Reveal, a plasma-only ctDNA assay that detects the presence of MRD by identifying somatic alterations and methylation signatures of cell-free DNA associated with colorectal cancer. Results: As of April 2021, 501 patients were enrolled in the COSMOS-CRC-01, of which 496 patients had their post-operative 4-week ctDNA status. In this analysis, we included the first 100 patients enrolled with clinical stage II or more CRC. Seven patients were excluded due to non-curative resection or pathological stage (pStage) IV. The assay was able to produce a result for all 93 samples analyzed (failure rate of 0%). MRD was detected in 23 (25%) patients 4 weeks after surgery. The MRD detection rate was 20% in pStage II disease and 29% in pStage III disease. Patients with positive MRD were older than those with negative MRD ( p = 0.0001). Across all MRD positive samples, 30%, 9%, and 61% were positive by both genomic and epigenomic, only genomic, and only epigenomic calls. Genomic signatures included APC, BRAF, KRAS, and TP53 mutations with the lowest variant allelic fraction of 0.04%. With a median follow-up time of 12.2 months (range 8-18 months), 9 of 93 patients recurred (9.7%). ctDNA was detected from a single 4-week post-surgical sample in 55% of patients who recurred (5 of 9). 1-year disease-free survival was 81.2% in patients with positive MRD and 93.9% in those with negative MRD (hazard ratio 3.49, 95% CI 0.93–13.10, p = 0.049). Multivariate analysis including baseline characteristics associated with recurrence risk showed that MRD status had the strongest association with the recurrence. Post-operative 4-week serum CEA level was not associated with risk for recurrence. Conclusions: While follow-up in this cohort is currently limited, the results suggest that a single post-surgery sample run on a plasma-only assay that integrates genomic and epigenomic signatures can more accurately stratify patients with CRC by recurrence risk than previously known clinical factors. Data from baseline and longitudinal timepoints will be reported as available along with longer term clinical follow-up. Clinical trial information: UMIN000037765.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
GIN的应助被Reaper采纳,获得10
1秒前
陈攀完成签到,获得积分10
3秒前
3秒前
二三发布了新的文献求助10
3秒前
ding的应助被JH_Yang采纳,获得10
3秒前
112完成签到 ,获得积分10
3秒前
思源的应助被嘻嘻哈哈顺利采纳,获得30
5秒前
zgm完成签到,获得积分10
5秒前
5秒前
王人捷发布了新的文献求助30
7秒前
搜集达人的应助被追寻夏槐采纳,获得20
7秒前
BIGDUCK完成签到,获得积分10
8秒前
FashionBoy的应助被vc采纳,获得10
8秒前
9秒前
10秒前
GG酱发布了新的文献求助30
10秒前
酷波er的应助被眼睛大初之采纳,获得10
11秒前
12秒前
田様的应助被鹦鹉采纳,获得10
12秒前
黄橙橙完成签到 ,获得积分10
13秒前
13秒前
syvshc的应助被含蓄的冰绿采纳,获得10
14秒前
lucky完成签到 ,获得积分10
15秒前
15秒前
16秒前
Ferry完成签到,获得积分10
17秒前
17秒前
JH_Yang发布了新的文献求助10
18秒前
Nole的应助被hannah采纳,获得10
19秒前
zZZZ发布了新的文献求助10
20秒前
20秒前
Ryan发布了新的文献求助10
20秒前
21秒前
西红柿发布了新的文献求助10
21秒前
123发布了新的文献求助10
21秒前
欢呼半山完成签到 ,获得积分10
21秒前
22秒前
22秒前
桐桐的应助被清水烫春菜采纳,获得10
24秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Agyptische Geschichte der 21.30. Dynastie 510
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
基于界面调控的高效湿气发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8192776
求助须知:如何正确求助?哪些是违规求助? 9579206
关于积分的说明 21864151
捐赠科研通 7792348
什么是DOI,文献DOI怎么找? 3437041
关于科研通互助平台的介绍 2560633
邀请新用户注册赠送积分活动 2483916